Biomarkers /
BRAF
Back to Biomarkers List
Overview
BRAF (B-Raf proto-oncogene, serine/threonine kinase) is a gene that encodes the protein serine/threonine-protein kinase B-raf. BRAF is involved in many cellular processes, including cell proliferation, differentiation, and transcriptional regulation. Mutant BRAF has been implicated in the pathogenesis of several cancers, including melanoma, non-small cell lung cancer, colorectal cancer, papillary thyroid cancer, and ovarian cancer (PMID: 12068308).
Biomarker-Directed Therapies
BRAF is a predictive biomarker for use of vemurafenib, dabrafenib, trametinib, encorafenib, cetuximab, cobimetinib, panitumumab, binimetinib, pembrolizumab, atezolizumab, cemiplimab, dasatinib, and imatinib in patients.
Melanoma, colorectal carcinoma, non-small cell lung carcinoma, ganglioglioma, and pilocytic astrocytoma have the most therapies with BRAF as a predictive biomarker.
Of the therapies with BRAF as a predictive biomarker, 10 are FDA-approved in at least one clinical setting and 11 have NCCN guidelines in at least one clinical setting.
BRAF V600E, BRAF Codon 600 Missense, BRAF V600K, BRAF V600D, and BRAF V600G are the top alterations on BRAF targeted by therapies [4].
Cetuximab +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: May Decrease Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely. Joint guidance from ASCO, AMP, CAP, and ASCP makes no recommendation for or against BRAF status as a predictive molecular biomarker, citing insufficient evidence. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: May Decrease Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely. The detected alteration (V600_K601delinsE) includes the V600E change plus a deletion of the adjacent amino acid, and in vitro evidence identifies it as a gain of function mutation, similar to V600E alone. Joint guidance from ASCO, AMP, CAP, and ASCP makes no recommendation for or against BRAF status as a predictive molecular biomarker, citing insufficient evidence. |
Dabrafenib +
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE, BNF, SMC) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE, SMC) | |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy with dabrafenib is recommended, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Thyroid Gland Follicular Carcinoma -
Thyroid Gland Papillary Carcinoma -
Dasatinib +
Non-Small Cell Lung Carcinoma -
Encorafenib +
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Imatinib +
Gastrointestinal Stromal Tumor -
Panitumumab +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: May Decrease Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely. Joint guidance from ASCO, AMP, CAP, and ASCP makes no recommendation for or against BRAF status as a predictive molecular biomarker, citing insufficient evidence. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: May Decrease Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely. The detected alteration (V600_K601delinsE) includes the V600E change plus a deletion of the adjacent amino acid, and in vitro evidence identifies it as a gain of function mutation, similar to V600E alone. Joint guidance from ASCO, AMP, CAP, and ASCP makes no recommendation for or against BRAF status as a predictive molecular biomarker, citing insufficient evidence. |
Pembrolizumab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with a ROS1, RET, BRAF V600E, or MET Exon 14 Skipping alteration: approved as a single agent for first- or subsequent-line therapy. However, per NCCN, targeted therapy for the oncogenic driver should take precedence over an immune checkpoint inhibitor. |
Trametinib +
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Trametinib is FDA approved for single-agent use to treat patients with unresectable or metastatic melanoma with BRAF V600E/K; however, trametinib monotherapy is no longer an NCCN-recommended treatment option due to relatively poor efficacy compared with BRAF inhibitor monotherapy and BRAF/MEK inhibitor combination therapy. |
Vemurafenib +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Theoretical Primary Resistance |
| Clinical Setting(s): Metastatic (MCG) |
Erdheim-Chester Disease -
Hairy Cell Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Theoretical Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) | |
| Note: Hairy Cell Leukemia, a subtype of Mature B-Cell Lymphoma/Leukemia, harboring BRAF V600E mutation responded to vemurafenib in two patients who had refractory disease or were in relapse after conventional therapies. |
Mature B-Cell Lymphoma/Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Theoretical Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) | |
| Note: Hairy Cell Leukemia (HCL), a subtype of Mature B-Cell Lymphoma/Leukemia harboring BRAF V600E mutation responded to vemurafenib in two patients who had refractory disease or were in relapse after conventional therapies. |
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, single-agent vemurafenib is an option if the combination of dabrafenib + trametinib is not tolerated. |
Thyroid Gland Follicular Carcinoma -
Thyroid Gland Papillary Carcinoma -
Atezolizumab + Cobimetinib + Vemurafenib +
Melanoma -
Binimetinib + Encorafenib +
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Approved for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended by NCCN if a BRAF V600 activating mutation is present. |
Cetuximab + Encorafenib +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved for metastatic colorectal cancer with a BRAF V600E mutation after prior therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely, unless given with a BRAF inhibitor. The detected alteration (V600_K601delinsE) includes the V600E change plus a deletion of the adjacent amino acid, and in vitro evidence identifies it as a gain of function mutation, similar to V600E alone. |
Cobimetinib + Vemurafenib +
Ganglioglioma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity |
Pilocytic Astrocytoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Pleomorphic Xanthoastrocytoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Dabrafenib + Pembrolizumab + Trametinib +
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended as first line therapy (Category 2B). |
Dabrafenib + Trametinib +
Cholangiocarcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended for subsequent line treatment. |
Ganglioglioma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN), Metastatic (NCCN) | |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity. |
Non-Small Cell Lung Carcinoma -
Pilocytic Astrocytoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Pleomorphic Xanthoastrocytoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma -
Encorafenib + Panitumumab +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely, unless given with a BRAF inhibitor |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely, unless given with a BRAF inhibitor. The detected alteration (V600_K601delinsE) includes the V600E change plus a deletion of the adjacent amino acid, and in vitro evidence identifies it as a gain of function mutation, similar to V600E alone. |
Clinical Trials
BRAF status serves as an inclusion eligibility criteria in 242 clinical trials, of which 159 are open and 83 are closed. Of the trials that contain BRAF status as an inclusion criterion, 3 are early phase 1 (3 open), 73 are phase 1 (41 open), 40 are phase 1/phase 2 (29 open), 113 are phase 2 (76 open), 1 is phase 2/phase 3 (0 open), 11 are phase 3 (9 open), and 1 is no phase specified (1 open).
Trials with BRAF status in the inclusion eligibility criteria most commonly target melanoma, malignant solid tumor, non-small cell lung carcinoma, colorectal carcinoma, and cutaneous melanoma [4].
The most frequent alterations to serve as inclusion eligibility criteria are BRAF V600E, BRAF Codon 600 Missense, BRAF Mutation, and BRAF V600K [4].
Trametinib, dabrafenib, vemurafenib, encorafenib, and binimetinib are the most frequent therapies in trials with BRAF as an inclusion criteria [4].
Significance of BRAF in Diseases
Melanoma +
BRAF is an inclusion criterion in 106 clinical trials for melanoma, of which 59 are open and 47 are closed. Of the trials that contain BRAF status and melanoma as inclusion criteria, 2 are early phase 1 (2 open), 32 are phase 1 (15 open), 20 are phase 1/phase 2 (12 open), 46 are phase 2 (26 open), and 6 are phase 3 (4 open) [4].
Dabrafenib, vemurafenib, binimetinib, encorafenib, cobimetinib, trametinib, atezolizumab, and pembrolizumab have evidence of efficacy in patients with BRAF mutation in melanoma [4].
Non-Small Cell Lung Carcinoma +
BRAF is an inclusion criterion in 37 clinical trials for non-small cell lung carcinoma, of which 27 are open and 10 are closed. Of the trials that contain BRAF status and non-small cell lung carcinoma as inclusion criteria, 17 are phase 1 (12 open), 5 are phase 1/phase 2 (4 open), and 15 are phase 2 (11 open) [4].
Dabrafenib, trametinib, dasatinib, pembrolizumab, and vemurafenib have evidence of efficacy in patients with BRAF mutation in non-small cell lung carcinoma [4].
Colorectal Carcinoma +
BRAF is an inclusion criterion in 27 clinical trials for colorectal carcinoma, of which 15 are open and 12 are closed. Of the trials that contain BRAF status and colorectal carcinoma as inclusion criteria, 13 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), 8 are phase 2 (3 open), and 2 are phase 3 (2 open) [4].
Cetuximab, encorafenib, and panitumumab have evidence of efficacy in patients with BRAF mutation in colorectal carcinoma [4].
Thyroid Gland Papillary Carcinoma +
BRAF is an inclusion criterion in 6 clinical trials for thyroid gland papillary carcinoma, of which 4 are open and 2 are closed. Of the trials that contain BRAF status and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 4 are phase 2 (3 open) [4].
Dabrafenib and vemurafenib have evidence of efficacy in patients with BRAF mutation in thyroid gland papillary carcinoma [4].
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +
BRAF is an inclusion criterion in 5 clinical trials for thyroid gland undifferentiated (anaplastic) carcinoma, of which 5 are open and 0 are closed. Of the trials that contain BRAF status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [4].
Dabrafenib and trametinib have evidence of efficacy in patients with BRAF mutation in thyroid gland undifferentiated (anaplastic) carcinoma [4].
Hairy Cell Leukemia +
BRAF is an inclusion criterion in 4 clinical trials for hairy cell leukemia, of which 4 are open and 0 are closed. Of the trials that contain BRAF status and hairy cell leukemia as inclusion criteria, 4 are phase 2 (4 open) [4].
Vemurafenib has evidence of efficacy in patients with BRAF mutation in hairy cell leukemia [4].
Cholangiocarcinoma +
BRAF is an inclusion criterion in 3 clinical trials for cholangiocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Dabrafenib and trametinib have evidence of efficacy in patients with BRAF mutation in cholangiocarcinoma [4].
Thyroid Gland Follicular Carcinoma +
BRAF is an inclusion criterion in 3 clinical trials for thyroid gland follicular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Dabrafenib and vemurafenib have evidence of efficacy in patients with BRAF mutation in thyroid gland follicular carcinoma [4].
Pilocytic Astrocytoma +
BRAF is an inclusion criterion in 2 clinical trials for pilocytic astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and pilocytic astrocytoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].
Cobimetinib, vemurafenib, dabrafenib, and trametinib have evidence of efficacy in patients with BRAF mutation in pilocytic astrocytoma [4].
Erdheim-Chester Disease +
BRAF is an inclusion criterion in 1 clinical trial for Erdheim-Chester disease, of which 0 are open and 1 is closed. Of the trial that contains BRAF status and Erdheim-Chester disease as inclusion criteria, 1 is phase 2 (0 open) [4].
Vemurafenib has evidence of efficacy in patients with BRAF mutation in Erdheim-Chester disease [4].
Ganglioglioma +
BRAF is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib, vemurafenib, dabrafenib, and trametinib have evidence of efficacy in patients with BRAF mutation in ganglioglioma [4].
Mature B-Cell Lymphoma/Leukemia +
Vemurafenib has evidence of efficacy in patients with BRAF mutation in mature B-cell lymphoma/leukemia [4].
Pleomorphic Xanthoastrocytoma +
Cobimetinib, vemurafenib, dabrafenib, and trametinib have evidence of efficacy in patients with BRAF mutation in pleomorphic xanthoastrocytoma [4].
Malignant Solid Tumor +
BRAF is an inclusion criterion in 68 clinical trials for malignant solid tumor, of which 48 are open and 20 are closed. Of the trials that contain BRAF status and malignant solid tumor as inclusion criteria, 36 are phase 1 (21 open), 10 are phase 1/phase 2 (9 open), and 22 are phase 2 (18 open) [4].
Cutaneous Melanoma +
BRAF is an inclusion criterion in 12 clinical trials for cutaneous melanoma, of which 10 are open and 2 are closed. Of the trials that contain BRAF status and cutaneous melanoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 2 are phase 3 (2 open) [4].
Glioma +
BRAF is an inclusion criterion in 10 clinical trials for glioma, of which 7 are open and 3 are closed. Of the trials that contain BRAF status and glioma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [4].
Multiple Myeloma +
BRAF is an inclusion criterion in 10 clinical trials for multiple myeloma, of which 8 are open and 2 are closed. Of the trials that contain BRAF status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (5 open) [4].
Breast Carcinoma +
BRAF is an inclusion criterion in 8 clinical trials for breast carcinoma, of which 6 are open and 2 are closed. Of the trials that contain BRAF status and breast carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [4].
Pancreatic Carcinoma +
BRAF is an inclusion criterion in 7 clinical trials for pancreatic carcinoma, of which 7 are open and 0 are closed. Of the trials that contain BRAF status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [4].
Cancer +
BRAF is an inclusion criterion in 6 clinical trials for cancer, of which 1 is open and 5 are closed. Of the trials that contain BRAF status and cancer as inclusion criteria, 5 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Low Grade Glioma +
BRAF is an inclusion criterion in 6 clinical trials for low grade glioma, of which 6 are open and 0 are closed. Of the trials that contain BRAF status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [4].
Ovarian Carcinoma +
BRAF is an inclusion criterion in 6 clinical trials for ovarian carcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRAF status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].
Colorectal Adenocarcinoma +
BRAF is an inclusion criterion in 5 clinical trials for colorectal adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRAF status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 2/phase 3 (0 open) [4].
Gastric Carcinoma +
BRAF is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BRAF status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 2 (2 open) [4].
Melanoma Of Unknown Primary +
BRAF is an inclusion criterion in 5 clinical trials for melanoma of unknown primary, of which 3 are open and 2 are closed. Of the trials that contain BRAF status and melanoma of unknown primary as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Non-Hodgkin Lymphoma +
BRAF is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 3 are open and 2 are closed. Of the trials that contain BRAF status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 4 are phase 2 (3 open) [4].
Thyroid Gland Carcinoma +
BRAF is an inclusion criterion in 5 clinical trials for thyroid gland carcinoma, of which 5 are open and 0 are closed. Of the trials that contain BRAF status and thyroid gland carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Head And Neck Squamous Cell Carcinoma +
BRAF is an inclusion criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 2 are closed. Of the trials that contain BRAF status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].
Poorly Differentiated Thyroid Gland Carcinoma +
BRAF is an inclusion criterion in 4 clinical trials for poorly differentiated thyroid gland carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BRAF status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].
Squamous Cell Lung Carcinoma +
BRAF is an inclusion criterion in 4 clinical trials for squamous cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BRAF status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Adenocarcinoma Of The Gastroesophageal Junction +
BRAF is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 3 are phase 2 (3 open) [4].
Bladder Carcinoma +
BRAF is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and bladder carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].
Esophageal Carcinoma +
BRAF is an inclusion criterion in 3 clinical trials for esophageal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].
Esophageal Squamous Cell Carcinoma +
BRAF is an inclusion criterion in 3 clinical trials for esophageal squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Gastrointestinal Stromal Tumor +
BRAF is an inclusion criterion in 3 clinical trials for gastrointestinal stromal tumor, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and gastrointestinal stromal tumor as inclusion criteria, 3 are phase 2 (3 open) [4].
Head And Neck Carcinoma +
BRAF is an inclusion criterion in 3 clinical trials for head and neck carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF status and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Lymphoma +
BRAF is an inclusion criterion in 3 clinical trials for lymphoma, of which 1 is open and 2 are closed. Of the trials that contain BRAF status and lymphoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Malignant Glioma +
BRAF is an inclusion criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].
Pancreatic Ductal Adenocarcinoma +
BRAF is an inclusion criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Renal Cell Carcinoma +
BRAF is an inclusion criterion in 3 clinical trials for renal cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].
Thyroid Gland Adenocarcinoma +
BRAF is an inclusion criterion in 3 clinical trials for thyroid gland adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF status and thyroid gland adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 1 is no phase specified (1 open) [4].
Urothelial Carcinoma +
BRAF is an inclusion criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and urothelial carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].
Acute Myeloid Leukemia +
BRAF is an inclusion criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].
Anaplastic Pleomorphic Xanthoastrocytoma +
BRAF is an inclusion criterion in 2 clinical trials for anaplastic pleomorphic xanthoastrocytoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Cervical Carcinoma +
BRAF is an inclusion criterion in 2 clinical trials for cervical carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and cervical carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Chronic Myelomonocytic Leukemia +
BRAF is an inclusion criterion in 2 clinical trials for chronic myelomonocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and chronic myelomonocytic leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].
Colon Carcinoma +
BRAF is an inclusion criterion in 2 clinical trials for colon carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRAF status and colon carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].
Germ Cell Tumor +
BRAF is an inclusion criterion in 2 clinical trials for germ cell tumor, of which 1 is open and 1 is closed. Of the trials that contain BRAF status and germ cell tumor as inclusion criteria, 2 are phase 2 (1 open) [4].
Hepatocellular Carcinoma +
BRAF is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and hepatocellular carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Histiocytic And Dendritic Cell Neoplasm +
BRAF is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain BRAF status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [4].
Langerhans Cell Histiocytosis +
BRAF is an inclusion criterion in 2 clinical trials for langerhans cell histiocytosis, of which 1 is open and 1 is closed. Of the trials that contain BRAF status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].
Lung Carcinoma +
BRAF is an inclusion criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Malignant Salivary Gland Neoplasm +
BRAF is an inclusion criterion in 2 clinical trials for malignant salivary gland neoplasm, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and malignant salivary gland neoplasm as inclusion criteria, 2 are phase 2 (2 open) [4].
Mucosal Melanoma +
BRAF is an inclusion criterion in 2 clinical trials for mucosal melanoma, of which 1 is open and 1 is closed. Of the trials that contain BRAF status and mucosal melanoma as inclusion criteria, 2 are phase 2 (1 open) [4].
Myelodysplastic Syndromes +
BRAF is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [4].
Non-Squamous Non-Small Cell Lung Carcinoma +
BRAF is an inclusion criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Pancreatic Adenocarcinoma +
BRAF is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and pancreatic adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Small Cell Lung Carcinoma +
BRAF is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Soft Tissue Sarcoma +
BRAF is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Ameloblastoma +
BRAF is an inclusion criterion in 1 clinical trial for ameloblastoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF status and ameloblastoma as inclusion criteria, 1 is phase 2 (0 open) [4].
Anaplastic Ganglioglioma +
BRAF is an inclusion criterion in 1 clinical trial for anaplastic ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and anaplastic ganglioglioma as inclusion criteria, 1 is phase 2 (1 open) [4].
Astrocytic Tumor +
BRAF is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
B-Cell Non-Hodgkin Lymphoma +
BRAF is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Bile Duct Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Biliary Tract Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Bronchogenic Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Cervical Squamous Cell Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Chronic Lymphocytic Leukemia +
BRAF is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Colon Adenocarcinoma +
BRAF is an inclusion criterion in 1 clinical trial for colon adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and colon adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].
Diffuse Glioma +
BRAF is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Dysembryoplastic Neuroepithelial Tumor +
BRAF is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Embryonal Rhabdomyosarcoma +
BRAF is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Endometrial Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Gallbladder Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Gangliocytoma +
BRAF is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Gastric Adenocarcinoma +
BRAF is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Glioblastoma +
BRAF is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Hepatobiliary Neoplasm +
BRAF is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Histiocytic Sarcoma +
BRAF is an inclusion criterion in 1 clinical trial for histiocytic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and histiocytic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Histiocytosis +
BRAF is an inclusion criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [4].
Hodgkin Lymphoma +
BRAF is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF status and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Juvenile Xanthogranuloma +
BRAF is an inclusion criterion in 1 clinical trial for juvenile xanthogranuloma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and juvenile xanthogranuloma as inclusion criteria, 1 is phase 2 (1 open) [4].
Lip And Oral Cavity Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Low-Grade Neuroepithelial Tumor, NOS +
BRAF is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Malignant Central Nervous System Neoplasm +
BRAF is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Female Reproductive System Neoplasm +
BRAF is an inclusion criterion in 1 clinical trial for malignant female reproductive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant female reproductive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Hepatobiliary Neoplasm +
BRAF is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Laryngeal Neoplasm +
BRAF is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Peripheral Nerve Sheath Tumor +
BRAF is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Malignant Uterine Neoplasm +
BRAF is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Merkel Cell Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for Merkel cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and Merkel cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Metastatic Malignant Neoplasm In The Brain +
BRAF is an inclusion criterion in 1 clinical trial for metastatic malignant neoplasm in the brain, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and metastatic malignant neoplasm in the brain as inclusion criteria, 1 is phase 2 (1 open) [4].
Nasal Cavity And Paranasal Sinus Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nasopharyngeal Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Neuroblastoma +
BRAF is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Neurofibroma +
BRAF is an inclusion criterion in 1 clinical trial for neurofibroma, of which 0 are open and 1 is closed. Of the trial that contains BRAF status and neurofibroma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Neurofibromatosis Type 1 +
BRAF is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [4].
Neuronal And Mixed Neuronal-Glial Tumors +
BRAF is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Optic Nerve Glioma +
BRAF is an inclusion criterion in 1 clinical trial for optic nerve glioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and optic nerve glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Oropharyngeal Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Papillary Craniopharyngioma +
BRAF is an inclusion criterion in 1 clinical trial for papillary craniopharyngioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and papillary craniopharyngioma as inclusion criteria, 1 is phase 2 (1 open) [4].
Pilomyxoid Astrocytoma +
BRAF is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Primary Brain Neoplasm +
BRAF is an inclusion criterion in 1 clinical trial for primary brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and primary brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Prostate Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Rectal Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and rectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Rhabdoid Tumor +
BRAF is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Schwannoma +
BRAF is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Skin Squamous Cell Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for skin squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and skin squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Small Intestinal Adenocarcinoma +
BRAF is an inclusion criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Solid Neoplasm +
BRAF is an inclusion criterion in 1 clinical trial for solid neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BRAF status and solid neoplasm as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Splenic Diffuse Red Pulp Small B-Cell Lymphoma +
BRAF is an inclusion criterion in 1 clinical trial for splenic diffuse red pulp small B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and splenic diffuse red pulp small B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Squamous Cell Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF status and squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Thymic Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid Gland Squamous Cell Carcinoma +
BRAF is an inclusion criterion in 1 clinical trial for thyroid gland squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and thyroid gland squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
